Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial.

MLA

Ebert, Matthias P., et al. “Second-Line Therapy with Nivolumab plus Ipilimumab for Older Patients with Oesophageal Squamous Cell Cancer (RAMONA): A Multicentre, Open-Label Phase 2 Trial.” The Lancet. Healthy Longevity, vol. 3, no. 6, June 2022, pp. e417–27. EBSCOhost, https://doi.org/10.1016/S2666-7568(22)00116-7.

APA

Ebert, M. P., Meindl-Beinker, N. M., Gutting, T., Maenz, M., Betge, J., Schulte, N., Zhan, T., Weidner, P., Burgermeister, E., Hofheinz, R., Vogel, A., Angermeier, S., Bolling, C., de Wit, M., Jakobs, R., Karthaus, M., Stocker, G., Thuss-Patience, P., Leidig, T., … Haertel, N. (2022). Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial. The Lancet. Healthy Longevity, 3(6), e417–e427. https://doi.org/10.1016/S2666-7568(22)00116-7

Chicago

Ebert, Matthias P, Nadja M Meindl-Beinker, Tobias Gutting, Martin Maenz, Johannes Betge, Nadine Schulte, Tianzuo Zhan, et al. 2022. “Second-Line Therapy with Nivolumab plus Ipilimumab for Older Patients with Oesophageal Squamous Cell Cancer (RAMONA): A Multicentre, Open-Label Phase 2 Trial.” The Lancet. Healthy Longevity 3 (6): e417–27. doi:10.1016/S2666-7568(22)00116-7.